chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: U
Vaccine: COVID19
Symptoms: Vaccination complication
Clinical narrative: 1st shot, seems lik I had all the symptoms; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (1st shot, seems lik I had all the symptoms) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.     On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (1st shot, seems lik I had all the symptoms). At the time of the report, VACCINATION COMPLICATION (1st shot, seems lik I had all the symptoms) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter. Treatment information was not provided.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Received Expired Dose of Vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received Expired Dose of Vaccine) in a 64-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 25-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-May-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received Expired Dose of Vaccine). On 25-May-2021, EXPIRED PRODUCT ADMINISTERED (Received Expired Dose of Vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 26-May-2021: Follow up was received on 26 May 2021 included no new information.
Sex: U
Vaccine: COVID19
Symptoms: Malaise, Product dose omission issue
Clinical narrative: very ill for a couple of days; I did not get second dose; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (very ill for a couple of days) and PRODUCT DOSE OMISSION ISSUE (I did not get second dose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Patient had"Covid19" virus back in late November.     On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MALAISE (very ill for a couple of days) and PRODUCT DOSE OMISSION ISSUE (I did not get second dose). At the time of the report, MALAISE (very ill for a couple of days) outcome was unknown and PRODUCT DOSE OMISSION ISSUE (I did not get second dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided. Treatment information was not provided.  Patient had the Covid19 virus back in late November.
Sex: U
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Injection site sore; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Injection site sore) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (Injection site sore). At the time of the report, VACCINATION SITE PAIN (Injection site sore) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Concomitant medication were reported.  No treatment medication were reported.
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure increased, Blood pressure measurement, Electrocardiogram, Nausea, Vertigo
Clinical narrative: High blood pressure; nauseous; vertigo; This spontaneous case was reported by a patient and describes the occurrence of VERTIGO (vertigo), NAUSEA (nauseous) and BLOOD PRESSURE INCREASED (High blood pressure) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Hay fever, Allergy to animals (Dogs), Allergy to animals (Cats), Hypothyroidism since 1997, Hashimoto's thyroiditis since 1997, Osteoarthritis, Allergy to topical drugs (Demerol), Allergy to antibiotic (Povidine) and Lactose intolerance. Concomitant products included LEVOTHYROXINE SODIUM (UNITHROID), CYANOCOBALAMIN (VITAMIN B12 [CYANOCOBALAMIN]) and MELATONIN for an unknown indication, MAGNESIUM, FISH OIL and PROBIOTIC 10.   In April 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In April 2021, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 05-Feb-2021 at 3:00 PM, the patient experienced VERTIGO (vertigo). On 05-May-2021, the patient experienced BLOOD PRESSURE INCREASED (High blood pressure). In May 2021, the patient experienced NAUSEA (nauseous). On 05-Feb-2021, VERTIGO (vertigo) had resolved. At the time of the report, NAUSEA (nauseous) had resolved and BLOOD PRESSURE INCREASED (High blood pressure) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In May 2021, Blood pressure measurement: 160/95 (High) High 160/95. In May 2021, Electrocardiogram: normal (normal) Normal.         No concomitant medications were reported.  No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 27-Jul-2021: Follow up information recived on 27-Jul-2021: Significant follow up-Concomitant added,allergy added,outcome updated for high blood pressure.Different start date of same dose On 27-Jul-2021: Follow up received on 27-Jul-2021::Non-significant follow up
Sex: F
Vaccine: COVID19
Symptoms: Fibromyalgia
Clinical narrative: her Fibromyalgia pain came back; This spontaneous case was reported by a pharmacist and describes the occurrence of FIBROMYALGIA (her Fibromyalgia pain came back) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 2 dosage form. On 05-Feb-2021, the patient experienced FIBROMYALGIA (her Fibromyalgia pain came back). At the time of the report, FIBROMYALGIA (her Fibromyalgia pain came back) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not reported.  Treatment information was not provided.
Sex: U
Vaccine: COVID19
Symptoms: Chills, Pyrexia
Clinical narrative: Fever; Chills; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever) and CHILLS (Chills) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PYREXIA (Fever) and CHILLS (Chills). At the time of the report, PYREXIA (Fever) and CHILLS (Chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Concomitant medications were reported. No treatment medications were reported.   Reporter did not allow further contact
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: Husband not able to receive dose 2 within the recommended time frame; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Husband not able to receive dose 2 within the recommended time frame) in a 50-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Husband not able to receive dose 2 within the recommended time frame). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Husband not able to receive dose 2 within the recommended time frame) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided. Treatment information was not provided.   This case was linked to MOD-2021-098866 (Patient Link).
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Myalgia, Nausea
Clinical narrative: body aches; 101 fever; chills; nausea; had extreme fatigue; headache; The second (or 2.5) dose; This spontaneous case was reported by a patient and describes the occurrence of OVERDOSE (The second (or 2.5) dose), MYALGIA (body aches), PYREXIA (101 fever), CHILLS (chills) and NAUSEA (nausea) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 05-Apr-2021 at 2:15 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-May-2021, the patient experienced OVERDOSE (The second (or 2.5) dose). On an unknown date, the patient experienced MYALGIA (body aches), PYREXIA (101 fever), CHILLS (chills), NAUSEA (nausea), FATIGUE (had extreme fatigue) and HEADACHE (headache). At the time of the report, OVERDOSE (The second (or 2.5) dose), MYALGIA (body aches), PYREXIA (101 fever), CHILLS (chills), NAUSEA (nausea), FATIGUE (had extreme fatigue) and HEADACHE (headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided.  No treatment medications were provided.   This case was linked to MOD-2021-073091 (Patient Link).
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Overdose, Pyrexia
Clinical narrative: body aches; 101 fever; chills; nausea; had extreme fatigue; headache; The second (or 2.5) dose; This spontaneous case was reported by a patient and describes the occurrence of OVERDOSE (The second (or 2.5) dose), MYALGIA (body aches), PYREXIA (101 fever), CHILLS (chills) and NAUSEA (nausea) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 05-Apr-2021 at 2:15 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-May-2021, the patient experienced OVERDOSE (The second (or 2.5) dose). On an unknown date, the patient experienced MYALGIA (body aches), PYREXIA (101 fever), CHILLS (chills), NAUSEA (nausea), FATIGUE (had extreme fatigue) and HEADACHE (headache). At the time of the report, OVERDOSE (The second (or 2.5) dose), MYALGIA (body aches), PYREXIA (101 fever), CHILLS (chills), NAUSEA (nausea), FATIGUE (had extreme fatigue) and HEADACHE (headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided.  No treatment medications were provided.   This case was linked to MOD-2021-073091 (Patient Link).
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Myalgia, Night sweats, Pyrexia
Clinical narrative: she had very high fever 102.3F; chills; extreme body aches; fatigue, Still feeling fatigue.; woke up with night sweats,her bed sheets, pillows, linen and hair completely soaked with sweats; arm hurt,really sore after both vaccines; This spontaneous case was reported by a consumer and describes the occurrence of NIGHT SWEATS (woke up with night sweats,her bed sheets, pillows, linen and hair completely soaked with sweats), VACCINATION SITE PAIN (arm hurt,really sore after both vaccines), PYREXIA (she had very high fever 102.3F), CHILLS (chills) and MYALGIA (extreme body aches) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039K20A and 027L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Asthma. Concomitant products included SALBUTAMOL SULFATE (ALBUTEROL [SALBUTAMOL SULFATE]) for Asthma, THYROID (ARMOUR THYROID) for an unknown indication.   On 31-Dec-2020 at 10:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 28-Jan-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced VACCINATION SITE PAIN (arm hurt,really sore after both vaccines). On 30-Jan-2021, the patient experienced NIGHT SWEATS (woke up with night sweats,her bed sheets, pillows, linen and hair completely soaked with sweats). On an unknown date, the patient experienced PYREXIA (she had very high fever 102.3F) and CHILLS (chills). an unknown date, the patient experienced MYALGIA (extreme body aches) and FATIGUE (fatigue, Still feeling fatigue.). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at a dose of 500 mg three times a day. At the time of the report, NIGHT SWEATS (woke up with night sweats,her bed sheets, pillows, linen and hair completely soaked with sweats), VACCINATION SITE PAIN (arm hurt,really sore after both vaccines), PYREXIA (she had very high fever 102.3F), CHILLS (chills), MYALGIA (extreme body aches) and FATIGUE (fatigue, Still feeling fatigue.) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was not applicable.   This case was linked to MOD-2021-019200, MOD-2021-019200 (Patient Link).
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: she had very high fever 102.3F; chills; extreme body aches; fatigue, Still feeling fatigue.; woke up with night sweats,her bed sheets, pillows, linen and hair completely soaked with sweats; arm hurt,really sore after both vaccines; This spontaneous case was reported by a consumer and describes the occurrence of NIGHT SWEATS (woke up with night sweats,her bed sheets, pillows, linen and hair completely soaked with sweats), VACCINATION SITE PAIN (arm hurt,really sore after both vaccines), PYREXIA (she had very high fever 102.3F), CHILLS (chills) and MYALGIA (extreme body aches) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039K20A and 027L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Asthma. Concomitant products included SALBUTAMOL SULFATE (ALBUTEROL [SALBUTAMOL SULFATE]) for Asthma, THYROID (ARMOUR THYROID) for an unknown indication.   On 31-Dec-2020 at 10:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 28-Jan-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced VACCINATION SITE PAIN (arm hurt,really sore after both vaccines). On 30-Jan-2021, the patient experienced NIGHT SWEATS (woke up with night sweats,her bed sheets, pillows, linen and hair completely soaked with sweats). On an unknown date, the patient experienced PYREXIA (she had very high fever 102.3F) and CHILLS (chills). an unknown date, the patient experienced MYALGIA (extreme body aches) and FATIGUE (fatigue, Still feeling fatigue.). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at a dose of 500 mg three times a day. At the time of the report, NIGHT SWEATS (woke up with night sweats,her bed sheets, pillows, linen and hair completely soaked with sweats), VACCINATION SITE PAIN (arm hurt,really sore after both vaccines), PYREXIA (she had very high fever 102.3F), CHILLS (chills), MYALGIA (extreme body aches) and FATIGUE (fatigue, Still feeling fatigue.) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was not applicable.   This case was linked to MOD-2021-019200, MOD-2021-019200 (Patient Link).
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Inappropriate schedule of product administration, Product dose omission issue
Clinical narrative: Patient tested positive for COVID-19; Patient received 1st dose over 3 months ago; Patient received 1st dose over 3 months ago; This spontaneous case was reported by a pharmacist and describes the occurrence of COVID-19 (Patient tested positive for COVID-19), PRODUCT DOSE OMISSION ISSUE (Patient received 1st dose over 3 months ago) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received 1st dose over 3 months ago) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 immunisation.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced COVID-19 (Patient tested positive for COVID-19), PRODUCT DOSE OMISSION ISSUE (Patient received 1st dose over 3 months ago) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received 1st dose over 3 months ago). At the time of the report, COVID-19 (Patient tested positive for COVID-19) outcome was unknown and PRODUCT DOSE OMISSION ISSUE (Patient received 1st dose over 3 months ago) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received 1st dose over 3 months ago) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Received Expired Dose of Vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received Expired Dose of Vaccine) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 25-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-May-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received Expired Dose of Vaccine). On 25-May-2021, EXPIRED PRODUCT ADMINISTERED (Received Expired Dose of Vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant details were provided. No treatment details were provided.
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039K20A and 013L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 02-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage form. On 30-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 02-Jan-2021, the patient experienced PAIN IN EXTREMITY (sore arm). The patient was treated with IBUPROFEN (MOTRIN IB) at a dose of UNK, qd. On 04-Jan-2021, PAIN IN EXTREMITY (sore arm) had resolved.            Relevant concomitant product usage were not reported by the reporter   This case was linked to MOD-2021-022506 (Patient Link).
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Feeling abnormal, Pyrexia
Clinical narrative: Foggy feeling in head; Fatigue; Fever; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (Foggy feeling in head), FATIGUE (Fatigue) and PYREXIA (Fever) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriatic arthritis.    Concurrent medical conditions included Psoriatic arthritis.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced FEELING ABNORMAL (Foggy feeling in head), FATIGUE (Fatigue) and PYREXIA (Fever). At the time of the report, FEELING ABNORMAL (Foggy feeling in head), FATIGUE (Fatigue) and PYREXIA (Fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not reported. Treatment of these events were not provided.
Sex: M
Vaccine: COVID19
Symptoms: Psoriasis
Clinical narrative: Psoriasis aggravated; This spontaneous case was reported by a physician and describes the occurrence of PSORIASIS (Psoriasis aggravated) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) for Psoriasis aggravated.    No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form and RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) (Subcutaneous) 1 dosage form. On an unknown date, the patient experienced PSORIASIS (Psoriasis aggravated). At the time of the report, PSORIASIS (Psoriasis aggravated) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The concomitant medications were not reported.   Reporter did not allow further contact
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Gallbladder disorder, Pain, Pruritus, Speech disorder, Swelling
Clinical narrative: Itching and bottom swollen after COVID vaccine; Itching and bottom swollen after COVID vaccine; Extreme pain; Vomiting; Gall bladder not working; Impaired speech; Itching all over body; Swelling on face; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Itching and bottom swollen after COVID vaccine), SWELLING (Itching and bottom swollen after COVID vaccine), SPEECH DISORDER (Impaired speech), PRURITUS (Itching all over body) and SWELLING FACE (Swelling on face) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriasis.    The patient's past medical history included Ruptured appendix, Alcohol abuse (ABSTAIN FROM ALCOHOL), Appendectomy and Cesarean section. Concurrent medical conditions included Benign ovarian cyst, Psoriasis, Penicillin allergy (ITCHING AND SWELLING) and Drug allergy (ITCHING AND SWELLING). Concomitant products included PRAVASTATIN for Cholesterol high, TRAZODONE and DULOXETINE for Sleep disorder, METOPROLOL and CIPROFLOXACIN for an unknown indication.   On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to at an unspecified dose. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) 40 mg. On 28-Feb-2021, the patient experienced SPEECH DISORDER (Impaired speech), PRURITUS (Itching all over body) and SWELLING FACE (Swelling on face). On 02-Mar-2021, the patient experienced GALLBLADDER DISORDER (Gall bladder not working). On an unknown date, the patient experienced PRURITUS (Itching and bottom swollen after COVID vaccine), SWELLING (Itching and bottom swollen after COVID vaccine), PAIN (Extreme pain) and VOMITING (Vomiting). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) (oral) at an unspecified dose and frequency. On 03-Mar-2021, SPEECH DISORDER (Impaired speech) and PRURITUS (Itching all over body) had resolved. On 08-Mar-2021, SWELLING FACE (Swelling on face) had resolved. On 10-Mar-2021, GALLBLADDER DISORDER (Gall bladder not working), PAIN (Extreme pain) and VOMITING (Vomiting) had resolved. At the time of the report, PRURITUS (Itching and bottom swollen after COVID vaccine) and SWELLING (Itching and bottom swollen after COVID vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Lab data : Computed tomography scan (02 MAR 2021): Abdomen gall bladder was not working.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Swelling face, Vomiting
Clinical narrative: Itching and bottom swollen after COVID vaccine; Itching and bottom swollen after COVID vaccine; Extreme pain; Vomiting; Gall bladder not working; Impaired speech; Itching all over body; Swelling on face; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Itching and bottom swollen after COVID vaccine), SWELLING (Itching and bottom swollen after COVID vaccine), SPEECH DISORDER (Impaired speech), PRURITUS (Itching all over body) and SWELLING FACE (Swelling on face) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriasis.    The patient's past medical history included Ruptured appendix, Alcohol abuse (ABSTAIN FROM ALCOHOL), Appendectomy and Cesarean section. Concurrent medical conditions included Benign ovarian cyst, Psoriasis, Penicillin allergy (ITCHING AND SWELLING) and Drug allergy (ITCHING AND SWELLING). Concomitant products included PRAVASTATIN for Cholesterol high, TRAZODONE and DULOXETINE for Sleep disorder, METOPROLOL and CIPROFLOXACIN for an unknown indication.   On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to at an unspecified dose. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) 40 mg. On 28-Feb-2021, the patient experienced SPEECH DISORDER (Impaired speech), PRURITUS (Itching all over body) and SWELLING FACE (Swelling on face). On 02-Mar-2021, the patient experienced GALLBLADDER DISORDER (Gall bladder not working). On an unknown date, the patient experienced PRURITUS (Itching and bottom swollen after COVID vaccine), SWELLING (Itching and bottom swollen after COVID vaccine), PAIN (Extreme pain) and VOMITING (Vomiting). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) (oral) at an unspecified dose and frequency. On 03-Mar-2021, SPEECH DISORDER (Impaired speech) and PRURITUS (Itching all over body) had resolved. On 08-Mar-2021, SWELLING FACE (Swelling on face) had resolved. On 10-Mar-2021, GALLBLADDER DISORDER (Gall bladder not working), PAIN (Extreme pain) and VOMITING (Vomiting) had resolved. At the time of the report, PRURITUS (Itching and bottom swollen after COVID vaccine) and SWELLING (Itching and bottom swollen after COVID vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Lab data : Computed tomography scan (02 MAR 2021): Abdomen gall bladder was not working.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Dyspnoea, Mobility decreased
Clinical narrative: No energy; Shortness of breath; Could hardly walk; This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA (No energy), DYSPNOEA (Shortness of breath) and MOBILITY DECREASED (Could hardly walk) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ASTHENIA (No energy), DYSPNOEA (Shortness of breath) and MOBILITY DECREASED (Could hardly walk). The patient was treated with PARACETAMOL (TYLENOL) at a dose of 1 dosage form as required. At the time of the report, ASTHENIA (No energy), DYSPNOEA (Shortness of breath) and MOBILITY DECREASED (Could hardly walk) was resolving.            The concomitant medications were not reported.  Patient stated that she did not experience any injection site reactions with the second shot.  It was also reported that patient still have side effects ever since he took shot he said he feels like there is no energy.   This case was linked to MOD-2021-090319 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 25-Jul-2021: TCR received on 25-Jul-2021 narrative was updated and further follow up declined.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Blood pressure measurement, Nausea
Clinical narrative: loss of energy; Nauseous; This spontaneous case was reported by a physician and describes the occurrence of ASTHENIA (loss of energy) and NAUSEA (Nauseous) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Crohn's disease.    No Medical History information was reported.   On 10-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 2 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (unknown route) at an unspecified dose. On 13-Apr-2021, the patient experienced NAUSEA (Nauseous). On an unknown date, the patient experienced ASTHENIA (loss of energy). At the time of the report, ASTHENIA (loss of energy) outcome was unknown and NAUSEA (Nauseous) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In April 2021, Blood pressure measurement: 150/119 (abnormal) Abnormal.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Lab data: Red blood cell count - Low, B12 -Low, Iron -Low,
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Influenza like illness, Pain, Pain in extremity
Clinical narrative: flu like symptoms; pain in arm; pain; This spontaneous case was reported by a physician and describes the occurrence of INFLUENZA LIKE ILLNESS (flu like symptoms), PAIN IN EXTREMITY (pain in arm) and PAIN (pain) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriatic arthritis.    No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. and first dose of ADALIMUMAB (HUMIRA) (Subcutaneous) 1 dosage form. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (flu like symptoms), PAIN IN EXTREMITY (pain in arm) and PAIN (pain). At the time of the report, INFLUENZA LIKE ILLNESS (flu like symptoms), PAIN IN EXTREMITY (pain in arm) and PAIN (pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment information was not provided.   Reporter did not allow further contact
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Fatigue, Headache, Hypoaesthesia, Pain
Clinical narrative: Tingling; Numbness; Wearing off effect; Lost weight; Pain/Generalized aching; Fatigue; Headache; COVID-19; This spontaneous case was reported by a physician and describes the occurrence of COVID-19 (COVID-19), PARAESTHESIA (Tingling), HYPOAESTHESIA (Numbness), THERAPEUTIC RESPONSE SHORTENED (Wearing off effect) and WEIGHT DECREASED (Lost weight) in a 64-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) 40 milligram. On 26-Apr-2021, the patient experienced COVID-19 (COVID-19). On an unknown date, the patient experienced PARAESTHESIA (Tingling), HYPOAESTHESIA (Numbness), THERAPEUTIC RESPONSE SHORTENED (Wearing off effect), WEIGHT DECREASED (Lost weight), PAIN (Pain/Generalized aching), FATIGUE (Fatigue) and HEADACHE (Headache). At the time of the report, COVID-19 (COVID-19) and THERAPEUTIC RESPONSE SHORTENED (Wearing off effect) was resolving, PARAESTHESIA (Tingling), HYPOAESTHESIA (Numbness), WEIGHT DECREASED (Lost weight) and PAIN (Pain/Generalized aching) outcome was unknown and FATIGUE (Fatigue) and HEADACHE (Headache) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient lost 28 pounds, starting on an unknown date.  Very limited information regarding the events has been provided at this time.  Further information has been requested.; Sender's Comments: Very limited information regarding the events has been provided at this time.  Further information has been requested.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Paraesthesia, Therapeutic response shortened, Weight decreased
Clinical narrative: Tingling; Numbness; Wearing off effect; Lost weight; Pain/Generalized aching; Fatigue; Headache; COVID-19; This spontaneous case was reported by a physician and describes the occurrence of COVID-19 (COVID-19), PARAESTHESIA (Tingling), HYPOAESTHESIA (Numbness), THERAPEUTIC RESPONSE SHORTENED (Wearing off effect) and WEIGHT DECREASED (Lost weight) in a 64-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) 40 milligram. On 26-Apr-2021, the patient experienced COVID-19 (COVID-19). On an unknown date, the patient experienced PARAESTHESIA (Tingling), HYPOAESTHESIA (Numbness), THERAPEUTIC RESPONSE SHORTENED (Wearing off effect), WEIGHT DECREASED (Lost weight), PAIN (Pain/Generalized aching), FATIGUE (Fatigue) and HEADACHE (Headache). At the time of the report, COVID-19 (COVID-19) and THERAPEUTIC RESPONSE SHORTENED (Wearing off effect) was resolving, PARAESTHESIA (Tingling), HYPOAESTHESIA (Numbness), WEIGHT DECREASED (Lost weight) and PAIN (Pain/Generalized aching) outcome was unknown and FATIGUE (Fatigue) and HEADACHE (Headache) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient lost 28 pounds, starting on an unknown date.  Very limited information regarding the events has been provided at this time.  Further information has been requested.; Sender's Comments: Very limited information regarding the events has been provided at this time.  Further information has been requested.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dizziness, Fatigue, Headache, Injection site mass
Clinical narrative: dizziness; big lump; soreness of arm; arm swelled; injection site pain; Headache; Chills; Fatigue; Nausea; muscle pain all over body; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (dizziness), INJECTION SITE MASS (big lump), PAIN IN EXTREMITY (soreness of arm), PERIPHERAL SWELLING (arm swelled) and INJECTION SITE PAIN (injection site pain) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 immunization. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Apr-2021, the patient experienced DIZZINESS (dizziness), INJECTION SITE MASS (big lump), PAIN IN EXTREMITY (soreness of arm), PERIPHERAL SWELLING (arm swelled), INJECTION SITE PAIN (injection site pain), HEADACHE (Headache), CHILLS (Chills), FATIGUE (Fatigue), NAUSEA (Nausea) and MYALGIA (muscle pain all over body). At the time of the report, DIZZINESS (dizziness), INJECTION SITE MASS (big lump), PAIN IN EXTREMITY (soreness of arm), PERIPHERAL SWELLING (arm swelled), INJECTION SITE PAIN (injection site pain), HEADACHE (Headache), CHILLS (Chills), FATIGUE (Fatigue), NAUSEA (Nausea) and MYALGIA (muscle pain all over body) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided. Treatment information was not provided.    This case was linked to MOD-2021-090271 (Patient Link).   Reporter did not allow further contact
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site pain, Myalgia, Nausea, Pain in extremity, Peripheral swelling
Clinical narrative: dizziness; big lump; soreness of arm; arm swelled; injection site pain; Headache; Chills; Fatigue; Nausea; muscle pain all over body; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (dizziness), INJECTION SITE MASS (big lump), PAIN IN EXTREMITY (soreness of arm), PERIPHERAL SWELLING (arm swelled) and INJECTION SITE PAIN (injection site pain) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 immunization. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Apr-2021, the patient experienced DIZZINESS (dizziness), INJECTION SITE MASS (big lump), PAIN IN EXTREMITY (soreness of arm), PERIPHERAL SWELLING (arm swelled), INJECTION SITE PAIN (injection site pain), HEADACHE (Headache), CHILLS (Chills), FATIGUE (Fatigue), NAUSEA (Nausea) and MYALGIA (muscle pain all over body). At the time of the report, DIZZINESS (dizziness), INJECTION SITE MASS (big lump), PAIN IN EXTREMITY (soreness of arm), PERIPHERAL SWELLING (arm swelled), INJECTION SITE PAIN (injection site pain), HEADACHE (Headache), CHILLS (Chills), FATIGUE (Fatigue), NAUSEA (Nausea) and MYALGIA (muscle pain all over body) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided. Treatment information was not provided.    This case was linked to MOD-2021-090271 (Patient Link).   Reporter did not allow further contact
Sex: F
Vaccine: COVID19
Symptoms: Swelling, Swelling face
Clinical narrative: swollen region on her neck and jaw line; swollen region on her neck and jaw line; This spontaneous case was reported by a consumer and describes the occurrence of SWELLING (swollen region on her neck and jaw line) and SWELLING FACE (swollen region on her neck and jaw line) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 002C21A and 008B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 22-Apr-2021, the patient experienced SWELLING (swollen region on her neck and jaw line) and SWELLING FACE (swollen region on her neck and jaw line). At the time of the report, SWELLING (swollen region on her neck and jaw line) and SWELLING FACE (swollen region on her neck and jaw line) had not resolved.            Action taken with mRNA-1273 in response to the events was not applicable.  Concomitant medications were not provided.  Treatment information was not provided.   This case was linked to MOD-2021-089306 (Patient Link).
Sex: M
Vaccine: COVID19
Symptoms: Ill-defined disorder
Clinical narrative: Able to stick a magnet to his arm; This spontaneous case was reported by a consumer and describes the occurrence of ILL-DEFINED DISORDER (Able to stick a magnet to his arm) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ILL-DEFINED DISORDER (Able to stick a magnet to his arm). At the time of the report, ILL-DEFINED DISORDER (Able to stick a magnet to his arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The concomitant medications were not reported.  The treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 27-May-2021: The follow-up was received on 9-JUN-2021 and has no new information.
Sex: F
Vaccine: COVID19
Symptoms: Blister, Rash
Clinical narrative: blisters in her hands; rash on hand; This spontaneous case was reported by a consumer and describes the occurrence of BLISTER (blisters in her hands) and RASH (rash on hand) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced BLISTER (blisters in her hands) and RASH (rash on hand). At the time of the report, BLISTER (blisters in her hands) and RASH (rash on hand) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was reported.   Treatment medication was not provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 23-Jul-2021: Follow up received contains non significant information. Address updated.
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Dysstasia, Fatigue, Heart rate, Pain, Visual impairment
Clinical narrative: difficulty in standing; visual impairment; pain aggravated; fatigue aggravated; This spontaneous case was reported by a physician and describes the occurrence of DYSSTASIA (difficulty in standing), VISUAL IMPAIRMENT (visual impairment), PAIN (pain aggravated) and FATIGUE (fatigue aggravated) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced DYSSTASIA (difficulty in standing), VISUAL IMPAIRMENT (visual impairment), PAIN (pain aggravated) and FATIGUE (fatigue aggravated). At the time of the report, DYSSTASIA (difficulty in standing), VISUAL IMPAIRMENT (visual impairment), PAIN (pain aggravated) and FATIGUE (fatigue aggravated) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, Heart rate: increased (abnormal) increased.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was provided   Reporter did not allow further contact